What Interpharma Praha does

Interpharma Praha, a.s. (also known as IPP) was a Czech contract development and manufacturing organization (CDMO) that provided research, development, and manufacturing services in the fields of pharmaceutical active substances (léčivé substance) and nutraceuticals / food supplements (doplňky stravy). Legally registered as a joint-stock company (akciová společnost, or a.s.) on 31 December 1991, the firm was headquartered at Komořanská 955/61, Prague 4 – Modřany, Czech Republic, and operated as part of the wider Otsuka pharmaceutical network, with documented affiliation to Otsuka Novel Products and to OTSUKA Pharmaceutical Development and Commercialization, Inc. in Princeton, New Jersey. Day-to-day executive leadership rested with CEO Shin Ogasawara, COO and Board Member Ing. Ivan Hlaváček, CSc., and Head of Business Department Natalia Ziňkova, with PRK Partners providing external legal counsel.

The firm's core offering was pharmaceutical and nutraceutical development and manufacturing, but the source data does not disclose named product brands, specific formulations, a distinct technology platform, or proprietary process IP; the technical footprint is best characterized as conventional small-scale pharmaceutical and food supplement CDMO activity tied to the Otsuka group's pipeline. There is no app, API, AI/ML capability, integration, or notable digital product surface disclosed, and the company's own website search returns no matches for indexed product pages.

Commercially, Interpharma Praha functioned in a B2B, intra-group CDMO capacity with no publicly disclosed revenue, pricing model, customer list, or marketing or distribution channel activity. The company extended its geographic reach only within Central Europe (the Czech Republic), with all commercial coordination routed through the Otsuka parent and affiliate network. Citing changes in the business environment, Interpharma Praha terminated all business operations on March 31, 2026 and initiated the legal procedures required for liquidation.

Name

Interpharma Praha

Legal name

Interpharma Praha, a.s.

Website

https://interpharma-praha.com

Company type

Private

Founded year

1991

Operating status

Closed

Headcount range

1–10 employees

Short description

Interpharma Praha, a.s. was a Czech pharmaceutical and nutraceutical contract development and manufacturing organization (CDMO) operating within the Otsuka group, providing R&D and manufacturing services for drug substances and food supplements before ceasing operations on March 31, 2026.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract manufacturing
• Nutraceutical product development
• Drug substance manufacturing
• Contract research organization
• Dietary supplement manufacturing

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Core offering

Interpharma Praha, a.s. was a Contract Development and Manufacturing Organization (CDMO) that provided research, development, and manufacturing services for pharmaceutical substances and nutraceutical/dietary supplement products. The company operated within the Otsuka pharmaceutical group, serving affiliated entities from its facility in Prague 4 – Modřany, Czech Republic. All business operations ceased on March 31, 2026 and the company entered liquidation.

Product overview

Interpharma Praha, a.s. (IPP) was a Contract Development and Manufacturing Organization (CDMO) providing research, development, and manufacturing services in the fields of pharmaceuticals (léčivé substance) and nutraceuticals (doplňky stravy). The company operated as part of the Otsuka group, specifically aligned with Otsuka Novel Products and OTSUKA Pharmaceutical Development and Commercialization, Inc. Based in Prague 4 – Modřany, the company ceased all business operations on March 31, 2026, and initiated legal proceedings for liquidation. No specific named product brands, individual formulations, or distinct service modules were identified in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical R&D and Contract Manufacturing Services Contract research, development, and manufacturing services for pharmaceutical drug substances, delivered to affiliated Otsuka group entities (Otsuka Novel Products; OTSUKA Pharmaceutical Development and Commercialization, Inc.) from the Prague 4 – Modřany facility.
• Nutraceutical (Food Supplement) R&D and Contract Manufacturing Services Contract research, development, and manufacturing services for food supplements and nutraceutical products, delivered to affiliated Otsuka entities and channeled through the IPP Business Department.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Otsuka Novel ProductscoreStrategic or Co-development PartnerParent/affiliate company within the Otsuka group. Interpharma Praha operated as part of the Otsuka pharmaceutical network, providing manufacturing services for the group.
• OTSUKA Pharmaceutical Development and Commercialization, Inc.coreStrategic or Co-development PartnerU.S.-based affiliate located at 508 Carnegie Center Drive, Princeton, New Jersey 08540. Part of the Otsuka group that Interpharma Praha served, with coordination on pharmaceutical development and commercialization activities.

Scale indicators1 record

Recent moves4 records

Direct peers

• NextPharma: European CDMO offering pharmaceutical and nutraceutical manufacturing services across multiple dosage forms, directly comparable to Interpharma Praha's combination of regulated and consumer health CDMO work.
• PharmaZell: German API manufacturer and CDMO serving global pharmaceutical companies, comparable in its focus on small-molecule active ingredients and European regulatory expertise.
• Recipharm: Sweden-headquartered European CDMO providing contract development and manufacturing of pharmaceuticals, comparable in scope of small-molecule drug substance and drug product services.
• Hovione: Portugal-based CDMO specializing in small-molecule API development and manufacturing for global pharma, the most direct functional and geographic comparable to Interpharma Praha's drug-substance CDMO model.
• SEQENS: France-based integrated API and intermediates CDMO, closely aligned with Interpharma Praha's focus on small-molecule active substance manufacturing for global pharma clients.
• Alcami: US-based CDMO offering small-molecule API development and drug product manufacturing services, comparable in service portfolio to a niche pharma CDMO of Interpharma Praha's scale.
• Aenova Group: European CDMO combining prescription pharma development and manufacturing with nutraceutical/dietary supplement capabilities, mirroring Interpharma Praha's dual pharma + nutraceutical service mix.

Broad incumbents

• Lonza: Global CDMO leader with extensive small-molecule API and drug product capabilities, comparable as a broad incumbent in the same CDMO market in which Interpharma Praha operated.
• Catalent: Global large-scale CDMO providing development and manufacturing services across small and large molecules; broader in scope and scale than Interpharma Praha but operates in the same overall CDMO category.

Emerging players

• Eurofins CDMO: European contract development and manufacturing services arm of Eurofins, serving pharmaceutical and nutraceutical clients with overlapping CDMO capabilities relevant to a small European drug-substance manufacturer.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interpharma Praha